Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PPM1D | O15297 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15632355 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL27274652 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL31234239 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL144330 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL141264 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL15632374 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL1882303 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL9595376 | 1.00 | NR1H2 (0.36) | NR1H2CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL24540367 | 0.91 | ALDH1A1 (0.36) | CHRM2CHRM1CHRM3ALDH1A1TSHR | |
| SCHEMBL23555453 | 0.91 | ALDH1A1 (0.36) | CHRM2CHRM1CHRM3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORP (US) | 2024-11-28 | — | — | US | disclosed |
| WO-2024220532-A1 | PYRROLIDINE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION | 2024-03-28 | — | — | US | disclosed |
| WO-2024015731-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION (US) | 2024-01-18 | — | — | WO | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
| EP-3150617-B1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | CIPLA USA INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-RE47741-E1 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2019-11-26 | — | — | US | disclosed |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2011044503-A9 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| WO-2011044503-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2010147836-A1 | COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS | ACHAOGEN, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | NR1H2 1577/4885CHRM2 1937/4885CHRM1 1335/4885 |
| US-20120135946-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | NR1H2 2337/4885CHRM2 1977/4885CHRM1 1255/4885 |
| US-20100099661-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | NR1H2 1577/4885CHRM2 1937/4885CHRM1 1335/4885 |
| US-20240390340-A1 | PYRROLIDINE KRAS INHIBITORS | KRAS, NRAS, HRAS | NR1H2 2168/4885CHRM2 4876/4885CHRM1 4866/4885 |
| US-20120135945-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | NR1H2 2420/4885CHRM2 1954/4885CHRM1 1214/4885 |
| US-20240101557-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | KRAS, NRAS, HRAS | NR1H2 1035/4885CHRM2 4857/4885CHRM1 4860/4885 |
| US-20110288041-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, NQO2, QARS1 | NR1H2 2192/4885CHRM2 1970/4885CHRM1 1128/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | NR1H2 1577/4885CHRM2 1937/4885CHRM1 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.